Tirtha Chakraborty - Vor Biopharma Chief Officer
| VOR Stock | USD 0.79 0.01 1.25% |
Insider
Tirtha Chakraborty is Chief Officer of Vor Biopharma
| Age | 51 |
| Address | 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 655 6580 |
| Web | https://www.vorbio.com |
Tirtha Chakraborty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tirtha Chakraborty against Vor Biopharma stock is an integral part of due diligence when investing in Vor Biopharma. Tirtha Chakraborty insider activity provides valuable insight into whether Vor Biopharma is net buyers or sellers over its current business cycle. Note, Vor Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vor Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tirtha Chakraborty over two months ago Disposition of 5576 shares by Tirtha Chakraborty of Vor Biopharma at 0.83 subject to Rule 16b-3 | ||
Tirtha Chakraborty over three months ago Disposition of 876 shares by Tirtha Chakraborty of Vor Biopharma at 0.87 subject to Rule 16b-3 | ||
Tirtha Chakraborty over three months ago Disposition of 985 shares by Tirtha Chakraborty of Vor Biopharma at 0.94 subject to Rule 16b-3 | ||
Tirtha Chakraborty over three months ago Disposition of 5576 shares by Tirtha Chakraborty of Vor Biopharma at 5.51 subject to Rule 16b-3 |
Vor Biopharma Management Efficiency
The company has Return on Asset of (0.3974) % which means that on every $100 spent on assets, it lost $0.3974. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7807) %, meaning that it generated no profit with money invested by stockholders. Vor Biopharma's management efficiency ratios could be used to measure how well Vor Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.72. As of 11/25/2024, Net Tangible Assets is likely to grow to about 302.6 M, while Total Assets are likely to drop slightly above 151.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Johannes Houte | Nurix Therapeutics | 58 | |
| Prof MD | Ventyx Biosciences | N/A | |
| JD Esq | Nurix Therapeutics | 63 | |
| MPH MD | Foghorn Therapeutics | 51 | |
| Joo MD | Design Therapeutics | 61 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| David MD | Erasca Inc | 40 | |
| Allan MD | Foghorn Therapeutics | 49 | |
| Fanny Cavalie | Foghorn Therapeutics | 46 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Carlos Costa | Foghorn Therapeutics | 51 | |
| Melissa Brody | Kymera Therapeutics | N/A | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Christopher MD | Nuvalent | 55 | |
| Christian Itin | Autolus Therapeutics | 60 | |
| MD MBA | Shattuck Labs | 65 | |
| Michael LaCascia | Foghorn Therapeutics | 59 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 |
Vor Biopharma Leadership Team
Elected by the shareholders, the Vor Biopharma's board of directors comprises two types of representatives: Vor Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vor. The board's role is to monitor Vor Biopharma's management team and ensure that shareholders' interests are well served. Vor Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vor Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Chief Officer | ||
| Samir MS, Senior Management | ||
| Han MD, Chief Officer | ||
| Dr MBA, Chief Officer | ||
| Eyal MD, Chief Officer | ||
| Tania Philipp, Chief Officer | ||
| MBA MD, CEO Pres | ||
| Pharm PharmD, Chief Officer | ||
| Amy Quinlan, Interim Officer | ||
| Veit Schmelmer, VP Management | ||
| John MBA, Chief Development | ||
| David MBA, Senior Quality | ||
| Tirtha Chakraborty, Chief Officer | ||
| DPHIL MD, Scientific Board |
Vor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vor Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 24.3 M | ||||
| Shares Outstanding | 68.67 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 81.20 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Book | 0.74 X | ||||
| EBITDA | (114.37 M) | ||||
| Net Income | (117.86 M) |
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.